You are here

  • Home
  • Archive
  • Volume 9, Issue 4
  • Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial

Article metrics

Article menu
Oncolytic and local immunotherapy
Original research
Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial

 

Online download statistics by month:

Online download statistics by month: April 2021 to July 2025

AbstractFullPdf
Apr 2021459459244
May 202124224294
Jun 202116116177
Jul 202114314354
Aug 202114614665
Sep 2021989847
Oct 202114914970
Nov 202111711773
Dec 2021848742
Jan 2022525452
Feb 2022494965
Mar 2022141146103
Apr 202211112063
May 202210411176
Jun 202210911162
Jul 202212813856
Aug 20229610255
Sep 202211812868
Oct 202212913795
Nov 202215115379
Dec 202210911044
Jan 2023757742
Feb 202313513746
Mar 202317017562
Apr 202314314367
May 202310812645
Jun 2023787925
Jul 202310210348
Aug 202312412726
Sep 202315015026
Oct 202315215326
Nov 202316216439
Dec 202311011041
Jan 2024757732
Feb 2024535319
Mar 2024100101107
Apr 202411211257
May 2024757732
Jun 2024868543
Jul 2024666740
Aug 2024626219
Sep 2024535424
Oct 2024575730
Nov 2024818228
Dec 202413614657
Jan 2025898946
Feb 2025828754
Mar 202510010447
Apr 202510110148
May 2025808159
Jun 2025616335
Jul 2025110
Total587560042854